The European Medicines Agency (EMA) has recommended the suspension of Picato in the EU and EEA as a precautionary measure...
EMA has completed its review of Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, and concluded that the medicine may increase the risk of skin cancer and that its risks outweigh its benefits.
Results of long-term clearance rates of Actinic Keratosis lesions after treatment with Picato (ingenol mebutate gel), from Leo Pharma, demonstrated...
The FDA has approved Picato (ingenol mebutate) gel in the 0.015%/0.05% strength from Leo Pharma for the topical treatment of...
In a preliminary assessment, the German Institute for Quality and Efficiency in Health Care ( IQWiG) has concluded that Leo...
On 20 September 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...
Picato is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.